Chapter 5

Moving Beyond Metabolic Syndrome: Assessing Diabetes and Cardiometabolic Risk

K. Indulekha, C.S. Pitchumoni and V. Mohan


Association of metabolic abnormalities including glucose intolerance, hypertension, central obesity and dyslipidemia comprise what is called “Metabolic Syndrome (MS)”. It is known that MS is a risk factor for both diabetes and cardiovascular disease (CVD). Non-alcoholic fatty liver disease (NAFLD) has also emerged as an important metabolic disease which is associated with both diabetes and cardiovascular disease. South Asian countries and particularly India have very high prevalence rates of MS and NAFLD. Moreover, the prevalence of type 2 diabetes and premature coronary artery disease is very high. However, the link between MS, NAFLD and CVD are not very well defined. This chapter reviews in detail the association of MS with CVD and also NAFLD and CVD. It also discusses the controversies with MS and highlights current strategies involved in management of MS and NAFLD.

Total Pages: 85-101 (17)

Purchase Chapter  Book Details


.Phytotherapy in the Management of Diabetes and Hypertension.
.Phytotherapy in the Management of Diabetes and Hypertension.
.Frontiers in Clinical Drug Research – Diabetes and Obesity.
.Understanding Obesity: From its Causes to Impact on Life.
.Advances in Meat Processing Technologies.
.Food Additives and Human Health.
.Application of Alternative Food-Preservation Technologies to Enhance Food Safety and Stability.
.Anti-Obesity Drug Discovery and Development.